Association of serum fetuin-A levels with mortality in dialysis patients.

M.M. Hermans, V. Brandenburg, M. Ketteler, J.P. Kooman, F.M. van der Sande, E.W. Boeschoten, K.M.L. Leunissen, R.T. Krediet, F.W. Dekker, NECOSAD Netherlands cooperative study on the adequacy of Dialysis

Research output: Contribution to journalArticleAcademicpeer-review


Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and inducers. Fetuin-A, an acute phase glycoprotein, is one of the more powerful circulating inhibitors of hydroxyapatite formation. A prospective multicenter cohort study was initiated to include both hemodialysis (HD) and peritoneal dialysis (PD) patients in an evaluation of the association of serum fetuin-A levels with both cardiovascular (CV) and non-CV mortality. An increase in the serum fetuin-A concentration of 0.1 g/l was associated with a significant reduction in all-cause mortality of 13%. There was a significant 17% reduction in non-CV mortality and a near significant reduction in CV mortality. This association of fetuin-A and mortality rates was comparable in both HD and PD patients even when corrected for factors, including but not limited to age, gender, primary kidney disease, C-reactive protein levels, and nutritional status. We conclude that serum fetuin-A concentrations may be a general predictor of mortality in dialysis patients.

Original languageEnglish
Pages (from-to)202-207
JournalKidney International
Issue number2
Publication statusPublished - 1 Jan 2007

Cite this